GLP-1 receptor agonists

A new study suggests the drug’s influence over our brain’s control systems may attenuate behaviors linked to aggression, which, given the widespread use of these pharmaceuticals, could ultimately dampen the rate of violent crime.

Scientists have identified a new way to supercharge obesity drug semaglutide by targeting key neurons. It could dramatically boost GLP-1 weight-loss power and prevent the dreaded plateaus that not even this "wonder drug" has been able to circumvent.

Could glucagon-like peptide-1 receptor agonists (GLP-1 RAs) nix the inflammation that drives asthma? Maybe, according to a large national study of more than 27,000 older adults, which was presented to scientists last week.

A new study has shown that the popular GLP-1 weight loss drug semaglutide has the power to halt, and to some extent restore, cartilage in people suffering from osteoarthritis (OA). The finding hints at a possible use of the drug beyond weight loss.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking GLP-1s regain the pounds and return to their original size after 1.7 years. It questions whether we're relying on this "magic cure" too heavily.

The rise in popularity of GLP-1 receptor agonist drugs like Ozempic is causing a wider societal shift that is now rocking the food industry. And some are feeling the pain more than others, as people make fundamental changes to their lives and health.

The World Health Organization has finally made its recommendations on using GLP-1 therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or price. And scientists still have some concerns.

Scientists have failed to show that weight-loss wonder drug semaglutide can also slow the progress of Alzheimer's disease (AD), as two two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk.

Some people don’t lose enough weight after bariatric surgery, but a new study shows that adding a daily shot of GLP-1 drug liraglutide can help patients shed extra pounds and may reduce the need for further surgery.

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without adding side effects – in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity.

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.